U.S. markets closed

InMed Pharmaceuticals Inc. (INM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.8500+0.1700 (+6.34%)
At close: 01:00PM EST
2.8800 +0.03 (+1.05%)
After hours: 04:54PM EST

InMed Pharmaceuticals Inc.

815 West Hastings Street
Suite 310
Vancouver, BC V6C 1B4

Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Mr. Eric A. Adams B.S. Chem., M.I.B.Pres, CEO & Director363.17kN/A1964
Ms. Alexandra Diane-Janet Mancini M.Sc.Sr. VP of Clinical & Regulatory Affairs261.03kN/A1953
Dr. Eric Chih-Hsien HsuSr. VP of Preclinical R&D253.46kN/A1970
Dr. Sazzad Hossain M.Sc., Ph.D.Co-FounderN/AN/A1958
Mr. Michael Woudenberg P.Eng.Chief Operating OfficerN/AN/A1969
Colin ClancySr. Director of Investor RelationsN/AN/AN/A
Mr. Jerry P. GriffinVP of Sales & MarketingN/AN/AN/A
Dr. Shane A. Johnson Ph.D.Sr. VP & GM of BayMedicaN/AN/AN/A
Ms. Sarah Li C.P.A., CGAVP of Accounting, Controller & Principal Accounting OfficerN/AN/AN/A
Dr. Ado MuhammadSr. Consultant of Medical AffairsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Corporate Governance

InMed Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.